Arvind Natarajan, PhD

Arvind is the Head of the Program Management Office and Strategy for Cell and Gene Technical Development and Manufacturing at Novartis. In his role, Arvind is responsible for implementing portfolio strategy and processes for Cell and Gene programs (early / late phase development and commercial). Arvind previously served as the Global CMC Lead for the development and commercialization of Kymriah®. Prior to joining Novartis, Arvind worked for several years at Merck and Company on the development, commercialization, and supply of Keytruda, Zostavax, ProQuad, and Varivax. Arvind has a Ph.D. in Chemical Engineering from the University of Minnesota, and an MBA from Wharton.